Share this:

New Drug Approvals

PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an amino-salicylate anti-inflammatory agent for gastrointestinal use. Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid. It has a molecular weight of 153.14.

The structural formula is:

25 mar 2013

KYORIN Pharmaceutical has been marketing mesalazine drugs, PENTASA® Tablets

250mg, PENTASA ® Tablets 500mg and PENTASA ® Enema 1g in Japan while continuously engaging in the development for inflammatory bowel diseases (IBD), including Ulcerative colitis and Crohn’s disease.

 NEW

The development of PENTASA® Suppositories 1g has just been successfully completed as a new formulation, which is convenient to patients, that meets therapeutic needs for Ulcerative colitis

View original post

References

New Drug Approvals

Istradefylline (KW-6002) is a selective antagonist at the A_2A receptor. It has been found to be useful in the treatment of Parkinson’s disease.^[1] Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.

 

Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). “Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson’s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)”. Annals of Neurology63 (3): 295–302. doi:10.1002/ana.21315. PMID 18306243.

 

TUE 26 MAR 2013

Kyowa Hakko Kirin, has received approval for NOURIAST tablets 20 mg (istradefylline), a novel antiparkinsonian agent, has been approved for manufacturing and marketing in Japan.

NOURIAST is a selective adenosine A_2A receptor antagonist for Parkinson’s disease…

View original post 18 more words

Share this:

New Drug Approvals

Empagliflozin

26 March 2013

Boehringer Ingelheim and Eli Lilly and Company today announced the European Medicines Agency (EMA) has accepted for review a marketing authorisation application (MAA) for the investigational sodium glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, for the treatment of Type 2 Diabetes (T2D) in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment.

 

A New Drug Application (NDA) for empagliflozin was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of Type 2 Diabetes mellitus (T2D) in adults.

Empagliflozin is part of a class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. In clinical trials to date, SGLT2 inhibitors have been shown to reduce blood glucose by removing excess glucose independently of beta cell function and insulin resistance.

* Empagliflozin…

View original post 339 more words

Share this:

New Drug Approvals

ACAMPROSATE

MAR 26 2013

MHLW JAPAN has approved  Nippon Shinyaku Co’s Regtect (acamprosate) for support maintenance of abstinence in patients with alcohol dependence.

Acamprosate, also known as N-acetyl homotaurine and by the brand name Campral, is a drug used for treating alcohol dependence.

Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by antagonizing glutamatergic N-methyl-D-aspartate receptors and agonizing gamma-aminobutyric acid (GABA) type A receptors. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol.Certain serious side effects include diarrhea, allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.

Campral is manufactured and marketed in the United States by Forest Laboratories…

View original post 29 more words

Share this:

Pakistan Education News Blog

Fateh Muhammad Malik has assumed the charge of the Rector, International Islamic University Islamabad (IIUI) from Saturday.

The President of Pakistan, as Chancellor of the International Islamic University, Islamabad appointed him Rector as per clause 12(1) of the IIUI Ordinance 1985. Earlier, Dr. Manzoor Ahmad, the outgoing Rector of the university relinquished the charge of the post of the Rector on February 21 on completion of his tenure.

Prof. Fateh Muhammad Malik is a leading scholar on Iqbaliyat, Urdu language and literature. He was also Chairman, National Language Authority.

Professor Malik is the author of a number of books on Pakistan movement and literacy and cultural themes.

He also served as Professor and Director of the Institute of Pakistan Studies at the Quaid-e-Azam University, Islamabad and as Iqbal Professor at Heidelberg University in Germany. The Nation

View original post

Share this:

Blog On Pakistan

In this post we will discuss the most fundemental, and arguably the most important, way of determining status of economies from the perspective of ordinary people. We now deviate away from the issue of theoretical economics and focus on practical economics i.e. the real people’s situation. We will do this by using the data showing the number of people living below $1 a day. This is to determine extreme poverty levels.

In 2007/2008, “Human Development Report”, under “03 Human and income poverty: developing countries” section, enlisted the Population living below $1 a day (%) data. This data is also available online on: http://hdrstats.undp.org/indicators/23.html

Population living below $1 a day (%).

Percentage for the concerned countries is:

	India	Pakistan	China	Bangladesh
Total Population (in thousands) as of 2004	1,134,403	158,081	1,312,979	153,281
% of population living under $1 a day	34.3	17.0	9.9	41.3
Total number of People living under…

View original post 812 more words

Crunchy numbers

Flower from pakistan

The stats helper monkeys at WordPress.com mulled over how this blog did in 2010, and here’s a high level summary of its overall blog health:

The Blog-Health-o-Meter™ reads This blog is doing awesome!.

A Boeing 747-400 passenger jet can hold 416 passengers. This blog was viewed about 4,300 times in 2010. That’s about 10 full 747s.

In 2010, there was 1 new post, not terrible for the first year! There were 2 pictures uploaded, taking up a total of 54kb.

The busiest day of the year was October 4th with 45 views. The most popular post that day was Mianwali A city of saraiki speaking .

Where did they come from?

The top referring sites in 2010 were photos.raftaar.in, gulepakistan.co.cc, 74.125.67.100, larki.webs.com, and irfanalikhan.blogspot.com.

Some visitors came searching, mostly for chudai, pixpux.com, pixpux, http://www.pixpux.com, and mast chudai.

Attractions…

View original post 31 more words

Share this:

New Drug Approvals

Tecfidera

Biogen Idec Inc. won European Union backing for Tecfidera, one of the first therapies for multiple sclerosis available in an easy-to-take pill that analysts say may generate $3.25 billion in annual sales.

Current MS drugs, including Biogen’s Avonex and Tysabri, are given by injection or intravenous infusion, and patient anticipation for Tecfidera may drive it to capture as much as 20 percent of the market within a year, according to Eric Schmidt of Cowen & Co. Sanofi (SAN)’s oral MS drug, Aubagio, was also recommended for marketing authorization today in Europe.

Biogen’s drug, formerly known as BG-12, will follow Novartis AG’s Gilenya to the market in the EU as an oral option for the treatment of MS. Because of its safety profile and efficacy, Weston, Massachusetts-based Biogen’s Tecfidera may generate $3.25 billion by 2017

 

View original post

Click Here for Hot and Sexy Pakistani Girls Pictures and Wallpapers

Pakistan Hot Girls Blog

HOT Pakistani Girls are known world wide for their beauty, attractiveness, loyalty, and politeness. But now are days, these beautiful and attractive Pakistani Girls are also achieving new milestones in Education, Lifestyle, Fashion, Modeling and Sports. More and more Pakistani girls are working in different sectors of different industries and fueling the economy. The liberalization of these Beautiful Pakistani Girls and their acceptation throughout Pakistani Society would lead to the more prosperous Pakistan. This section includes the pictures of beautiful Pakistani Girls studying in Colleges, working in institutions, or having some good time with their friends. Click here to watch these Pakistani Girls Photos.

 

Hot and Sexy Pakistani Girls Pictures and Wallpapers

 

 

 

Well! You are here to see the hot and sexy images of the beautiful and sexy and hot school going young girls and hot…

View original post 964 more words

Share this:

New Drug Approvals

 

The FDA has opened the inside track to Novartis’ experimental lung cancer drug, which gained “Breakthrough Therapy” designation that speeds the development and review schedules for new treatments. The Swiss drug giant plans to file for approval the drug, now in mid-stage clinical trials, in early 2014. Since clinical development began in 2011, the program has advanced with lightning speed compared with those that take 10 years or so to trial before submitted for approval.

While there are no guarantees of an FDA approval for Novartis’ compound, code-named LDK378, the “breakthrough” tag provides an early nod to the potential of the candidate to improve treatment for patients with metastatic non-small cell lung cancer with anaplastic lymphoma kinase (ALK) mutations.

The “breakthrough” designation is also important because Novartis’ compound and others with the coveted status have a shot to be approved by the FDA without completing all three phases of…

View original post 148 more words